May 2, 2019: patient-centered care model improves viral suppression; subpar immune responses when baseline CD4 tops 500; when CD4 plummets despite viral suppression; vaccination, immunoglobulin, and hepatitis A exposure.
More than 80 percent of U.S. HIV transmissions in 2016 were from people who were unaware of their status or had been diagnosed but lost to follow-up.
Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
Real-world treatment efficacy high, but falls short of trials; parental communication and PrEP awareness among adolescent MSM; immunotherapy feasible in people with HIV and cancer; AIDS-defining illness increases mortality risk in lung cancer patients.
How food insecurity feeds inflammation; racial disparities in HPV16 prevalence; how HIV meds affect pre-existing neurocognitive impairment; central nervous system inflammation in the setting of HIV treatment success.
The first global comparison of adolescents who acquired HIV as newborns highlights the challenges around treatment for children in developing countries.